Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 4.

Scherrer, A U; von Wyl, V; Fux, C A; Opravil, M; Bucher, H C; Fayet, A; Decosterd, L A; Hirschel, B; Khanlari, B; Yerly, S; Klimkait, T; Furrer, H; Ledergerber, B; Günthard, H F (2010). Implementation of Raltegravir in routine clinical practice: Selection criteria for choosing this drug, virologic response rates, and characteristics of failures. JAIDS Journal of Acquired Immune Deficiency Syndromes, 53(4):464-471.

Lubomirov, R; di Iulio, J; Fayet, A; Colombo, S; Martinez, R; Marzolini, C; Furrer, H; Vernazza, P; Calmy, A; Cavassini, M; Ledergerber, B; Rentsch, K; Descombes, P; Buclin, Thierry; Decosterd, L A; Csajka, C; Telenti, A (2010). ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir. Pharmacogenetics and Genomics, 20(4):217-230.

Fayet, A; Béguin, A; Zanolari, B; Cruchon, S; Guignard, N; Telenti, A; Cavassini, M; Günthard, H F; Buclin, T; Biollaz, J; Rochat, B; Decosterd, L A (2009). A LC-tandem MS assay for the simultaneous measurement of new antiretroviral agents: Raltegravir, maraviroc, darunavir, and etravirine. Journal of Chromatography B, 877(11-12):1057-1069.

di Iulio, J; Fayet, A; Arab-Alameddine, M; Rotger, M; Lubomirov, R; Cavassini, M; Furrer, H; Günthard, H F; Colombo, S; Csajka, C; Eap, C B; Decosterd, L A; Telenti, A (2009). In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function. Pharmacogenetics and Genomics, 19(4):300-309.

This list was generated on Thu Aug 24 11:13:06 2017 CEST.